How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

677 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Hirsutism (Treatment)

hirsutism. Sibutramine (withdrawn from US market October 8, 2010 [ ] ): Weight loss with this anorectic agent improves hirsutism scores, androgen levels, and cardiovascular risk factors in women with polycystic ovary syndrome (PCOS). Cosmetic measures for hirsutism and their disadvantages are as follows: Hydrogen peroxide bleaching is not suitable for severe hirsutism. Plucking can cause skin irritation, folliculitis, and scarring. Waxing can cause skin irritation, folliculitis, and scarring. The wax

2014 eMedicine.com

182. Catatonia (Treatment)

malignant syndrome related conditions?]. L’Encéphale . 2009. Lee J, Teoh T, Lee TS. Catatonia and psychosis associated with sibutramine: a case report and pathophysiologic correlation. J Psychosom Res . 2008 Jan. 64(1):107-9. . Neto B. Catatonia with left temporal lesion on MRI: crossing borders. European Psychiatry . 2009. 24 supplement 1:S727. Wachtel L. Catatonia in autism: Etiology, incidence and treatment [abstract]. European Psychiatry . 2008. 23:S402-S402. Wachtel LE, Contrucci-Kuhn SA, Griffin M (...) -Bernal F, Huffman JC, Fricchione GL. Alternative treatment strategies for catatonia: A systematic review. Gen Hosp Psychiatry . 2017 Sep. 48:1-19. . Media Gallery of 0 Tables Table. Causes of Catatonia by Category Category Causes Neurologic conditions Neuroleptic malignant syndrome [ ] Administration of agents that block postsynaptic dopamine receptors* Administration of sibutramine [ ] (withdrawn from US market October 8, 2010) Withdrawal of lorazepam and other sedatives Akinetic-rigid syndrome Anti

2014 eMedicine.com

183. Polycystic Ovarian Syndrome (Treatment)

of its recommendations for limiting the use of the highest approved dose (80 mg) of the cholesterol-lowering medication simvastatin (Zocor) because of increased risk of muscle damage. The FDA required changes to the simvastatin label to add new contraindications (should not be used with certain medications) and dose limitations for using simvastatin with certain medications. [ ] Sibutramine On October 8, 2010, Abbott Laboratories and the FDA notified health care professionals and patients about (...) the voluntary withdrawal of the obesity drug sibutramine (Meridia) from the US market because of clinical trial data indicating an increased risk of heart attack and stroke. [ ] Previous Next: Metabolic Derangements In patients with polycystic ovarian syndrome (PCOS) who are obese, endocrine-metabolic parameters markedly improve after 4-12 weeks of dietary restriction. Their sex hormone–binding globulin (SHBG) levels rise, and free testosterone levels fall by 2-fold. [ ] Serum insulin and insulin-like

2014 eMedicine.com

186. Polycystic Ovarian Syndrome (Overview)

injury. Posted: March 1, 2012. Available at . Accessed: May 22, 2012. US Food and Drug Administration. Safety: statin drugs - drug safety communication: class labeling change. Posted: February 28, 2012. Available at . Accessed: May 22, 2012. US Food and Drug Administration. Safety: Zocor (simvastatin): label change - new restrictions, contraindications, and dose limitations. Posted: June 8, 2011. Available at . Accessed: May 22, 2012. US Food and Drug Administration. Safety: Meridia (sibutramine

2014 eMedicine.com

187. Stimulants (Treatment)

) Phentermine - Fastin, Ionamin, Adipex Pipradrol Sibutramine - Meridia (withdrawn from US market October 8, 2010) Schedule V These substances have an abuse potential less than those in schedule IV. Schedule V controlled substances consist of preparations containing limited quantities of certain narcotic drugs and are generally for antitussive and antidiarrheal purposes. These drugs are subject to state and local regulation, and a prescription may not be required. Schedule V stimulants include pyrovalerone (...) to stop sales and marketing of pemoline. Sibutramine (Meridia) is a combination serotonin and norepinephrine and dopamine reuptake inhibitor whose appetite-suppressive effects appear to be related to its noradrenergic action. When its noradrenergic activity is blocked, the appetite suppression is lost. Selective serotonin reuptake inhibitors cause initial transient anorexia without causing long-term weight loss. Sibutramine is no longer marketed. On October 8, 2010, Abbott and the US Food and Drug

2014 eMedicine.com

189. Unstable Angina (Overview)

. Safety: Meridia (sibutramine): market withdrawal due to risk of serious cardiovascular events. US Food and Drug Administration. October 8, 2010. Available at . Accessed: June 5, 2013. Soukoulis V, Boden WE, Smith SC Jr, O'Gara PT. Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon. Circ Res . 2014 Jun 6. 114(12):1944-58. . . Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical

2014 eMedicine.com

190. Polycystic Ovarian Syndrome (Follow-up)

of its recommendations for limiting the use of the highest approved dose (80 mg) of the cholesterol-lowering medication simvastatin (Zocor) because of increased risk of muscle damage. The FDA required changes to the simvastatin label to add new contraindications (should not be used with certain medications) and dose limitations for using simvastatin with certain medications. [ ] Sibutramine On October 8, 2010, Abbott Laboratories and the FDA notified health care professionals and patients about (...) the voluntary withdrawal of the obesity drug sibutramine (Meridia) from the US market because of clinical trial data indicating an increased risk of heart attack and stroke. [ ] Previous Next: Metabolic Derangements In patients with polycystic ovarian syndrome (PCOS) who are obese, endocrine-metabolic parameters markedly improve after 4-12 weeks of dietary restriction. Their sex hormone–binding globulin (SHBG) levels rise, and free testosterone levels fall by 2-fold. [ ] Serum insulin and insulin-like

2014 eMedicine.com

192. Stimulants (Follow-up)

) Phentermine - Fastin, Ionamin, Adipex Pipradrol Sibutramine - Meridia (withdrawn from US market October 8, 2010) Schedule V These substances have an abuse potential less than those in schedule IV. Schedule V controlled substances consist of preparations containing limited quantities of certain narcotic drugs and are generally for antitussive and antidiarrheal purposes. These drugs are subject to state and local regulation, and a prescription may not be required. Schedule V stimulants include pyrovalerone (...) to stop sales and marketing of pemoline. Sibutramine (Meridia) is a combination serotonin and norepinephrine and dopamine reuptake inhibitor whose appetite-suppressive effects appear to be related to its noradrenergic action. When its noradrenergic activity is blocked, the appetite suppression is lost. Selective serotonin reuptake inhibitors cause initial transient anorexia without causing long-term weight loss. Sibutramine is no longer marketed. On October 8, 2010, Abbott and the US Food and Drug

2014 eMedicine.com

193. Catatonia (Follow-up)

malignant syndrome related conditions?]. L’Encéphale . 2009. Lee J, Teoh T, Lee TS. Catatonia and psychosis associated with sibutramine: a case report and pathophysiologic correlation. J Psychosom Res . 2008 Jan. 64(1):107-9. . Neto B. Catatonia with left temporal lesion on MRI: crossing borders. European Psychiatry . 2009. 24 supplement 1:S727. Wachtel L. Catatonia in autism: Etiology, incidence and treatment [abstract]. European Psychiatry . 2008. 23:S402-S402. Wachtel LE, Contrucci-Kuhn SA, Griffin M (...) -Bernal F, Huffman JC, Fricchione GL. Alternative treatment strategies for catatonia: A systematic review. Gen Hosp Psychiatry . 2017 Sep. 48:1-19. . Media Gallery of 0 Tables Table. Causes of Catatonia by Category Category Causes Neurologic conditions Neuroleptic malignant syndrome [ ] Administration of agents that block postsynaptic dopamine receptors* Administration of sibutramine [ ] (withdrawn from US market October 8, 2010) Withdrawal of lorazepam and other sedatives Akinetic-rigid syndrome Anti

2014 eMedicine.com

195. Hirsutism (Follow-up)

hirsutism. Sibutramine (withdrawn from US market October 8, 2010 [ ] ): Weight loss with this anorectic agent improves hirsutism scores, androgen levels, and cardiovascular risk factors in women with polycystic ovary syndrome (PCOS). Cosmetic measures for hirsutism and their disadvantages are as follows: Hydrogen peroxide bleaching is not suitable for severe hirsutism. Plucking can cause skin irritation, folliculitis, and scarring. Waxing can cause skin irritation, folliculitis, and scarring. The wax

2014 eMedicine.com

196. Stimulants (Diagnosis)

) Phentermine - Fastin, Ionamin, Adipex Pipradrol Sibutramine - Meridia (withdrawn from US market October 8, 2010) Schedule V These substances have an abuse potential less than those in schedule IV. Schedule V controlled substances consist of preparations containing limited quantities of certain narcotic drugs and are generally for antitussive and antidiarrheal purposes. These drugs are subject to state and local regulation, and a prescription may not be required. Schedule V stimulants include pyrovalerone (...) to stop sales and marketing of pemoline. Sibutramine (Meridia) is a combination serotonin and norepinephrine and dopamine reuptake inhibitor whose appetite-suppressive effects appear to be related to its noradrenergic action. When its noradrenergic activity is blocked, the appetite suppression is lost. Selective serotonin reuptake inhibitors cause initial transient anorexia without causing long-term weight loss. Sibutramine is no longer marketed. On October 8, 2010, Abbott and the US Food and Drug

2014 eMedicine.com

197. Catatonia (Diagnosis)

malignant syndrome [ ] Administration of agents that block postsynaptic dopamine receptors* Administration of sibutramine [ ] (withdrawn from US market October 8, 2010) Withdrawal of lorazepam and other sedatives Akinetic-rigid syndrome Anti-NMDA receptor encephalitis [ ] Arachnoid cyst in right parietal region Astrocytoma Atrophy of left amygdala [ ] Autistic disorder [ , , , , , , , , , , ] Basilar artery thrombosis Bilateral hemorrhagic lesions of temporal lobes Cerebellar catalepsy Cerebral (...) and neuroleptic malignant syndrome related conditions?]. L’Encéphale . 2009. Lee J, Teoh T, Lee TS. Catatonia and psychosis associated with sibutramine: a case report and pathophysiologic correlation. J Psychosom Res . 2008 Jan. 64(1):107-9. . Neto B. Catatonia with left temporal lesion on MRI: crossing borders. European Psychiatry . 2009. 24 supplement 1:S727. Wachtel L. Catatonia in autism: Etiology, incidence and treatment [abstract]. European Psychiatry . 2008. 23:S402-S402. Wachtel LE, Contrucci-Kuhn SA

2014 eMedicine.com

198. Polycystic Ovarian Syndrome (Diagnosis)

injury. Posted: March 1, 2012. Available at . Accessed: May 22, 2012. US Food and Drug Administration. Safety: statin drugs - drug safety communication: class labeling change. Posted: February 28, 2012. Available at . Accessed: May 22, 2012. US Food and Drug Administration. Safety: Zocor (simvastatin): label change - new restrictions, contraindications, and dose limitations. Posted: June 8, 2011. Available at . Accessed: May 22, 2012. US Food and Drug Administration. Safety: Meridia (sibutramine

2014 eMedicine.com

199. Obesity (Overview)

, Waitzman NJ. A multivariate analysis of federally mandated school wellness policies on adolescent obesity. J Adolesc Health . 2011 Oct. 49(4):363-70. . Waters E, de Silva-Sanigorski A, Hall BJ, et al. Interventions for preventing obesity in children. Cochrane Database Syst Rev . 2011 Dec 7. 12:CD001871. . Daniels SR, Long B, Crow S, et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study. Pediatrics . 2007 Jul (...) . 120(1):e147-57. . Berkowitz R, Fujioka K, Daniels S, et al. Effects of sibutramine treatment in obese adolescents. A randomized trial. Ann Intern Med . July 2006. 145:81-90. . Abbott Laboratories agrees to withdraw its obesity drug Meridia. FDA, U.S. Food and Drug Administration. Available at . Accessed: October 8, 2010. Dunican KC, Desilets AR, Montalbano JK. Pharmacotherapeutic options for overweight adolescents. Ann Pharmacother . 2007 Sep. 41(9):1445-55. . Bray GA, Ryan DH. Drug treatment

2014 eMedicine Pediatrics

200. Obesity (Treatment)

Activity Oude et al concluded that, although no one treatment program can be conclusively recommended, combined behavioral lifestyle interventions produce a significant reduction in weight. Although orlistat and sibutramine (withdrawn from US market) may be used as adjuncts to lifestyle interventions, they must be carefully considered. [ ] Smoking tobacco reduces appetite and is used by many adults and some teenagers to prevent or limit weight gain. The deleterious consequences of smoking clearly (...) . . Coffield JE, Metos JM, Utz RL, Waitzman NJ. A multivariate analysis of federally mandated school wellness policies on adolescent obesity. J Adolesc Health . 2011 Oct. 49(4):363-70. . Waters E, de Silva-Sanigorski A, Hall BJ, et al. Interventions for preventing obesity in children. Cochrane Database Syst Rev . 2011 Dec 7. 12:CD001871. . Daniels SR, Long B, Crow S, et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled

2014 eMedicine Pediatrics

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>